Prostate cancer is the most common diagnosed invasive cancer in American men and is the second leading cause of cancer-related deaths. Although there are several therapies successful in treating early, localized stage prostate cancer, current treatment of advanced metastatic castration-resistant prostate cancer remains ineffective due to inevitable progression of resistance to first-line treatment with docetaxel. The natural product quercetin (3,3',4',5,7pentahydroxyflavone), a flavonoid compound ubiquitous in dietary plants, possesses evidenced potential in treating advanced metastatic castration-resistant prostate cancer. However, its poor bioavailability and moderate potency hinder its advancement into clinical therapy. In order to engineer quercetin derivatives with improved potency and pharmacokinetic profiles for the treatment of advanced metastatic prostate cancer, we started this study with creating a small library of alkylated derivatives of quercetin for in vitro evaluation. The biological data and chemical reactivity of quercetin and its derivatives reported in literature directed us to design 3,4',7-O-trialkylquercetins as our first batch of targets. Consequently, nine 3,4',7-O-trialkylquercetins, together with four 3,7-Odialkylquercetins, four 3,3',4',7-tetraalkylquercetins, and one 3,3',4'-O-trialkylquercetin, were prepared by one step O-alkylation of commercially available quercetin mediated by potassium carbonate. Their structures were determined by 1D and 2D NMR data, and HRMS. Their anti-proliferative activities towards both androgen-refractory and androgen-sensitive prostate cancer cells were evaluated using WST-1 cell proliferation assay. The acquired structure-activity relationships indicate that 3,7-O-dialkylquercetins rather than 3,4',7-O-trialkylquercetins were much more potent than quercetin towards prostate cancer cells.
Prostate cancer, the most common diagnosed invasive cancer in American men, is the second leading cause of cancer-related deaths. Even though most patients can recover from localized androgensensitive prostate cancer after an appropriate therapy, the prostate cancer will unfortunately relapse in around 2-3 years after recovery from the early, androgen-sensitive stage [1] . At this point, prostate cancer is no longer responding to hormone therapy and/or has metastasized to different areas of the body. This was referred to as Hormone-Refractory Prostate Cancer or Androgen-Independent Prostate Cancer, and recently was designated as Castration-Resistant Prostate Cancer (CRPC). The US FDA did approve numerous drugs for the treatment of both androgen-dependent and castration-resistant prostate cancer. Sadly, there are no FDAapproved drugs that can actually cure advanced metastatic CRPC. The current first-line chemotherapy for CRPC, docetaxel, can barely increase survival by an average of 2.4 years [2] . The patients' inevitable progression of resistance to docetaxel makes it become an even less effective chemotherapeutic for advanced metastatic CRPC. Very recently, FDA approved cabazitaxel as a second-line treatment for the patients refractory to the first-line docetaxel chemotherapy due to the fact that carbazitaxel is the only available chemotherapeutic that can improve survival (even though by only 2.4 months) for docetaxel-resistant patients [3] . There is thus an urgent need to search for effective chemotherapeutics for clinical treatment of advanced metastatic castration-resistant prostate cancer. Quercetin, 3,3',4',5,7-pentahydroxyflavone (1 in Scheme 1), is a flavonoid compound ubiquitous in plant food sources [4] . Quercetin was capable of inhibiting cell growth in the mouse prostate cancer cell line TRAMP-C2 with an IC 50 of 20 μM [5] [6] . Numerous studies demonstrated that quercetin was also capable of suppressing Benzyl Benzyl Benzyl Benzyl the growth of both androgen-sensitive (LNCaP) and androgenrefractory human prostate cancer cell lines (PC-3 and DU145) and that quercetin has no apparent toxicity against normal prostate epithelial cells [7] [8] . Maggiolini and co-workers first demonstrated that quercetin functioned as agonists for the mutant androgen receptor (AR) T877A so that it could inhibit the proliferation of LNCaP cells at low concentration. However, high concentration of quercetin may independently cause significant cytotoxicity without involving hormone receptor expression [9] .
Wang et al. reported that quercetin exhibited potential in vivo antiprostate tumor efficacy in an androgen-sensitive LAPC-4 xenograft prostate tumor mouse model using severe combined immunodeficiency (SCID) mice. It inhibited tumor growth by 3% when 0.2% was administered as a supplement in diet and by 15% when 0.4% was taken [10] . Quercetin can also significantly reduce PC-3 tumor volume and weight in 6-week old BALB/cA nude mice. The average weight of prostate tumors decreased from 0.242 g for the control group to 0.099 g for the quercetin treated group, implying the in vivo anti-prostate tumor potential of quercetin [11] .
The above-described cell-based and animal-based studies have evidenced that quercetin could be a good candidate for prostate cancer treatment. However, its poor bioavailability and moderate potency hinder its advancement into clinical therapy. In order to engineer quercetin derivatives with improved potency and a better pharmacokinetic profile for the treatment of advanced metastatic prostate cancer, we started this project by creating a small panel of alkylated derivatives of quercetin for in vitro evaluation. The structure-activity relationships will be used to direct our further structure modulation.
The structure-cytotoxicity relationships of methylquercetins summarized by Beutler et al. [12] showed that 3,4',7trimethylquercetin possessed better cytotoxicity than quercetin and other methylquercetins. Intriguingly, Rao et al. [13] summarized that methylation of the five phenolic hydroxyl groups in quercetin occurred gradually with the following sequential positions order: 4' > 7 > 3 > 3' > 5. The superposition of cytotoxic potency and chemical reactivity of quercetin derivatives directed us to synthesize a group of new 3,4',7-O-trialkylquercetins as our first batch of targets. Different alkyl groups were introduced to investigate the effect of their length and steric hindrance on the cell proliferation. The targets were proposed to be achieved by one-step alkylation of quercetin.
As shown in Scheme 1, we planned to synthesize our expected 3, 4',7-O-trialkylquercetins by treating one equivalent of quercetin with three equivalents of alkyl halide using DMF as solvent and potassium carbonate as base. Reaction of quercetin with the appropriate alkyl halide did provide us with the expected 3,4',7-Otrialkylquercetins as the major products, but in moderate yields (less than 25%). Assignments of three alkyl groups were based on the key HMBC correlations between CH 2 protons of ethyl groups (δ 4.10, 4.10, and 4.22) and C-3, C-7, and C-4' in derivative 6 as summarized in Figure 1 . Four 3,7-O-dialkylquercetins, four 3,3',4',7-O-tetraalkylquercetins, and one 3,3',4'-O-trialkylquercetin were also collected for structure-activity relationship studies. Similarly, the locations of the alkyl groups in 3,7-Odibutylquercetin (11) and in 3,3',4'-O-triethylquercetin (8) were also confirmed by the existence of key correlations in their HMBC spectra ( Figure 1 ). As shown in Table 2 , all signals in the 1 H-and 13 C-NMR spectra for compounds 6, 8, and 11 have been fully assigned based on the extensive interpretation of their COSY, HMQC, and HMBC data. Preparation and anti-proliferative activities of quercetin derivatives Natural Product Communications Vol. 10 (12) 2015 2115
Among the eighteen quercetin derivatives that we prepared, five of them (8, 14-17) are new compounds. Derivatives 2-7, 9-13, and 18-19 are known, but there are no reports available on their antiproliferative activity against prostate cancer cell lines, even though their in vitro effects have been investigated on other cancer cell models [12, 14] . It should be pointed out that the 4',7dialkylquercetins reported in Ref. [14] should be corrected as 3,7dialkylquercetins based on our HMBC data of 11 ( Figure 1 ).
The anti-proliferative effect of eighteen synthetic quercetin derivatives (at 50 µM) was evaluated against both androgensensitive (LNCaP) and androgen-refractory (DU145 and PC-3) human prostate cancer cell lines. WST-1 cell proliferation assay was selected for this evaluation because of its easy operation in a microtiter plate without washing steps. The procedure is described in the Experimental Section and the absorbance was measured using a microplate reader (Synergy HT) at a wavelength of 430 nm. As shown in Table 3 , alkylation of the hydroxyl groups at C-3, C-4', and C-7 in quercetin with short, linear alkyl groups (such as methyl groups in 3 and ethyl groups in 6) slightly increases the antiproliferative activity towards three human prostate cancer cell lines. However, potency was rapidly diminished when either branched alkyl groups (isopropyl in 16 and isopentyl in 17) or linear lengthy groups (propyl in 10, butyl in 12, pentyl in 14, and hexyl in 15) were introduced into these three positions. Incorporation of ethyl groups to 3,3',4'-hydroxyl groups in quercetin (8) led to neither gain nor loss in its inhibitory rate. Surprisingly, all four 3,7-Odialkylquercetins (2, 5, 9, and 11) exhibited significantly higher inhibitory rate than quercetin against the three prostate cancer cell lines at both concentrations. They were over 2-11 times more potent than quercetin in the cell culture based on the comparison of their IC 50 values with that of quercetin (Table 3 ). 
Each experiment was performed at least thrice in duplicate.
In conclusion, eighteen alkylated derivatives of quercetin were prepared by a semi-synthesized approach. Their anti-proliferative activity was evaluated against three human prostate cancer cell lines using WST-1 cell proliferation assay. The structure-activity relationships acquired show i) that simultaneous introduction of three bulky or lengthy alkyl groups to C-3, C-4' and C-7 hydroxyl groups of quercetin led to a major loss of anti-proliferative activity in prostate cancer cells; and ii) that incorporation of two methyl groups in 2, two ethyl groups in 5, two propyl groups in 9, and two butyl groups in 11 to C-3 and C-7 hydroxyl groups resulted in much more potent derivatives. Chemical manipulation of one phenolic hydroxyl group might be the best direction for the future.
Experimental
General: NMR spectra were obtained on a Bruker Fourier 300 spectrometer in CDCl 3 and CD 3 COCD 3 . The chemical shifts are given in δ (ppm) referenced to the respective solvent peak, and coupling constants are reported in Hz. All reagents and solvents were purchased from commercial sources and were used without further purification. Column chromatography was performed using silica gel (32-63 µm). Preparative thin-layer chromatography (PTLC) separations were carried out on 1000 µm AnalTech thin layer chromatography plates (Lot No.13401).
General procedure for the synthesis of alkylated quercetin derivatives:
To a solution of quercetin hydrate (1.0 equiv.) in DMF was added anhydrous K 2 CO 3 (3 equiv.), followed by the appropriate alkyl halide (3.0 equiv.). The reaction mixture was allowed to stir at room temperature for 12 to 48 h prior to being diluted with diethyl ether and ethyl acetate (300 mL in total, 1:1, v/v). The consequent mixture was rinsed with brine (30 mL × 5), and the organic layer was dried over anhydrous MgSO 4 , filtered and concentrated in vacuo to give the corresponding crude product.
Preparation of methylated derivatives of quercetin (2, 3, and 4):
These derivatives were prepared according to the general procedure from quercetin hydrate (320 mg, 1 mmol) in DMF (1 mL). PTLC purification of crude product, using 30% ethyl acetate in hexane as eluent, yielded compounds 2 (24 mg, 7% yield), 3 (83 mg, 24% yield), and 4 (21 mg, 6% yield). (5, 6, 7, and 8) :
3,7-O-Dimethylquercetin

Preparation of ethylated quercetin derivatives
These derivatives were synthesized from quercetin hydrate (640 mg, 2 mmol) in DMF (2 mL). The crude product was purified through a , 1H ), 4.18 (q, J = 6.9 Hz, 2H), 4.16 (q, J = 6.9 Hz, 2H), 4.08 (q, J = 6.9 Hz, 2H), 4.06 (q, J = 6.9 Hz, 2H), 1.500 (t, J = 6.9 Hz, 3 H), 1.498 (t, J = 6.9 Hz, 3 H), 1.44 (t, J = 6.9 Hz, 3H), 1.33 (t, J = 6.9 Hz, 3H). 13 Table 3 .
Preparation of propylated derivatives of quercetin (9 and 10):
These derivatives were synthesized from quercetin hydrate (200 mg, 0.59 mmol) in DMF (0.6 mL). The crude product was purified through a pad of silica gel, eluting with 33% ethyl acetate in hexanes, followed by repetitive PTLC, eluting with 33% ethyl acetate in hexanes, to yield compounds 9 (9 mg, 4% yield) and 10 (9 mg, 3.6 % yield). of quercetin (11, 12, and 13) : Table 3 . 
3,7-O-Dipropylquercetin
Preparation of butylated derivatives
These
Bioassay
Cell culture: All cell lines were initially purchased from American Type Culture Collection (ATCC TM ). The PC-3 prostate cancer cell line and the LNCaP prostate cancer cell line were routinely cultured in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin. Cultures were maintained in 5% carbon dioxide at a temperature of 37 o C. The DU-145 prostate cancer cells were routinely cultured in Eagle's Minimum Essential Medium (EMEM) supplemented with 10% FBS and 1% penicillin/ streptomycin.
WST-1 cell proliferation assay:
PC-3, DU-145, or LNCaP cells were plated in 96-well plates at a density of 3200 in each well in 200 µL of culture medium. The cells were then treated with either quercetin or synthesized quercetin derivatives separately at 2 different doses of 50 µM for 3 days, while equal treatment volumes of DMSO (0.25%) were used as vehicle control. The cells were cultured in a CO 2 incubator at 37ºC for 3 days. Ten µL of the premixed WST-1 cell proliferation reagent (Clontech) was added to each well. After mixing gently for 1 min on an orbital shaker, the cells were incubated for an additional 3 h at 37ºC. To ensure homogeneous distribution of color, it is important to mix gently on an orbital shaker for 1 min. The absorbance of each well was measured using a microplate reader (Synergy HT) at a wavelength of 430 nm. The IC 50 value is the concentration of each compound that inhibits cell proliferation by 50% under the experimental 2118 Natural Product Communications Vol. 10 (12) 2015 Al-Jabban et al.
conditions and is the average from at least triplicate determinations that are reproducible and statistically significant. For calculating the IC 50 values, a linear proliferative inhibition was made based on at least 5 dosages for each compound.
